DAWN GELLAR: Open Payments
NPI 1467985606 · QUINCY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$705 in 8 payments from 5 companies in 2025. Trend: 2023 $24 · 2024 $0 · 2025 $705
Food & beverage: $705
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $234 |
| ABBVIE INC. | 2 | $141 |
| Vanda Pharmaceuticals Inc. | 1 | $120 |
| Biogen, Inc. | 1 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $95 |
Products named: Auvelity, VRAYLAR, FANAPT, ZURZUVAE, CAPLYTA.
Industry payments across MA — which companies pay providers there.
